Protara Therapeutics, Inc.

Filed a patent for "combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer" on Mon, January 9, 2023

Filed a patent for "combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer" on Mon, February 27, 2023

Filed a patent for "combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of non-muscle invasive bladder cancer" on Mon, February 27, 2023